Eli Lilly and Company

Other

Athena Neurosciences, Inc.

Celia A Whitesitt

Jon Kevin Reel

Richard L Simon

Winston S Marshall

Mitchell I Steinberg

Sherryl L Lifer

Alan David Palkowitz

William Pfeifer

K Jeff Thrasher

Donald B Boyd

Sandra K Sigmund

Fariborz Mohamadi

Jill A Panetta

Michael LeRoy Phillips

John Kevin Shadle

Venkatraghavan Vasudevan

Eugene D Thorsett

James E Audia

Varghese John

Jeffrey S Nissen

Lee H Latimer

Kumiko Takeuchi

Leander Merritt

Kenneth Lee Hauser

Beverly K Folmer

David Kent Herron

John S Ward

Charles Howard Mitch

Steven James Quimby

Lawrence J Heinz

Venkatraghaven Vasudevan

Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds

This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with &bgr;-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

Treatment of alzheimer's disease employing inhibitors of cathepsin D

The present invention relates to therapeutically active compounds of the formula:

Heterocyclic compounds and their use

The present invention provides heterocyclic 2-aza-bicyclo[2.2.1]heptane compounds which are useful for modulating a muscarinic ptor.

Heterocyclic compounds

Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions

A method of protecting a warm-blooded mammal from the progression of Alzheimer's disease, which comprises administering an effective amount of a compound of general formula. ##STR1## in which: R.sup.1 represents an optionally substituted aromatic or heteroaromatic group;

Inhibitors of amyloid beta-protein production

This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with .beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

Benzylidene rhodanines

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonists

A compound of the formula I in which ##STR1## Z is O or S; R.sup.11 is a halogen atom;

Chemical compounds as inhibitors of amyloid beta protein production

This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonist intermediates

Growing community of inventors

Greenwood, IN, United States of America

Celia A Whitesitt